Share ownership Vanda Pharmaceuticals Inc.

VNDA

US9216591084

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-05-19 pm EDT			5-day change	1st Jan Change
5.990 ^USD	-1.48%		-4.47%	-32.09%

May. 07	Vanda Pharmaceuticals Inc., Q1 2026 Earnings Call, May 06, 2026
May. 06	Vanda Pharmaceuticals Inc. Raises Revenue Guidance for the Full-Year 2026	CI

Share class: Vanda Pharmaceuticals Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	60,135,562	54,427,700 ( 90.51 %)	0	90.51 %

Major shareholders: Vanda Pharmaceuticals Inc.

Name	Equities	%	Valuation
BlackRock Advisors LLC 11.23 %	6,640,507	11.23 %	47 M $
Renaissance Technologies LLC 6.36 %	3,759,559	6.36 %	27 M $
STATE STREET CORPORATION 5.102 %	3,015,562	5.102 %	21 M $
SSgA Funds Management, Inc. 5.102 %	3,015,562	5.102 %	21 M $
AIGH Capital Management LLC 4.652 %	2,750,000	4.652 %	20 M $
Mihael Polymeropoulos 4.576 %	2,704,496	4.576 %	19 M $
Vanguard Capital Management LLC 4.198 %	2,481,491	4.198 %	18 M $
Millennium Management LLC 3.182 %	1,881,001	3.182 %	13 M $
Acadian Asset Management LLC 3.038 %	1,795,592	3.038 %	13 M $
DFA Australia Ltd. 2.924 %	1,728,089	2.924 %	12 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	73.88%
Individuals	8.54%
State Street Corp.	5.1%
Other	4.52%
SEI Investments Co.	0.12%
Manulife Financial Corp.	0.03%
Unknown	7.81%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	76.81%
Individuals	8.54%
Australia	2.92%
United Kingdom	1.6%
Canada	0.77%
Ireland	0.56%
Monaco	0.41%
Norway	0.23%
Germany	0.22%
Netherlands	0.05%
China	0.04%
Spain	0.02%
Hong Kong	0.01%
South Korea	0.01%

Based on 1000 largest holdings

Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Companyâ€™s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.

Employees

533

Sector

Biotechnology & Medical Research

More about the company